chr14-36516742-G-A
Variant names:
Variant summary
Our verdict is Benign. The variant received -9 ACMG points: 0P and 9B. BP4_StrongBS1_SupportingBS2
The NM_001079668.3(NKX2-1):c.*536C>T variant causes a 3 prime UTR change involving the alteration of a non-conserved nucleotide. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.0000066 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00017 ( 0 hom. )
Failed GnomAD Quality Control
Consequence
NKX2-1
NM_001079668.3 3_prime_UTR
NM_001079668.3 3_prime_UTR
Scores
2
Clinical Significance
Conservation
PhyloP100: 2.27
Publications
0 publications found
Genes affected
NKX2-1 (HGNC:11825): (NK2 homeobox 1) This gene encodes a protein initially identified as a thyroid-specific transcription factor. The encoded protein binds to the thyroglobulin promoter and regulates the expression of thyroid-specific genes but has also been shown to regulate the expression of genes involved in morphogenesis. Mutations and deletions in this gene are associated with benign hereditary chorea, choreoathetosis, congenital hypothyroidism, and neonatal respiratory distress, and may be associated with thyroid cancer. Multiple transcript variants encoding different isoforms have been found for this gene. This gene shares the symbol/alias 'TTF1' with another gene, transcription termination factor 1, which plays a role in ribosomal gene transcription. [provided by RefSeq, Feb 2014]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -9 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.55).
BS1
Variant frequency is greater than expected in population eas. GnomAdExome4 allele frequency = 0.000172 (14/81332) while in subpopulation EAS AF = 0.00123 (14/11394). AF 95% confidence interval is 0.000742. There are 0 homozygotes in GnomAdExome4. There are 7 alleles in the male GnomAdExome4 subpopulation. Median coverage is 0. This position passed quality control check. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
BS2
High AC in GnomAdExome4 at 14 AD gene.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_001079668.3. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| NKX2-1 | NM_001079668.3 | MANE Select | c.*536C>T | 3_prime_UTR | Exon 3 of 3 | NP_001073136.1 | P43699-3 | ||
| NKX2-1 | NM_003317.4 | c.*536C>T | 3_prime_UTR | Exon 2 of 2 | NP_003308.1 | P43699-1 | |||
| SFTA3 | NR_161364.1 | n.89+2726C>T | intron | N/A |
Ensembl Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| NKX2-1 | ENST00000354822.7 | TSL:1 MANE Select | c.*536C>T | 3_prime_UTR | Exon 3 of 3 | ENSP00000346879.6 | P43699-3 | ||
| NKX2-1 | ENST00000498187.6 | TSL:1 | c.*536C>T | 3_prime_UTR | Exon 2 of 2 | ENSP00000429607.2 | P43699-1 | ||
| SFTA3 | ENST00000546983.2 | TSL:4 | n.373+2243C>T | intron | N/A | ENSP00000449302.2 | F8VVG2 |
Frequencies
GnomAD3 genomes AF: 0.00000658 AC: 1AN: 152052Hom.: 0 Cov.: 32 show subpopulations
GnomAD3 genomes
AF:
AC:
1
AN:
152052
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.000172 AC: 14AN: 81332Hom.: 0 Cov.: 0 AF XY: 0.000187 AC XY: 7AN XY: 37448 show subpopulations
GnomAD4 exome
AF:
AC:
14
AN:
81332
Hom.:
Cov.:
0
AF XY:
AC XY:
7
AN XY:
37448
show subpopulations
African (AFR)
AF:
AC:
0
AN:
3880
American (AMR)
AF:
AC:
0
AN:
2494
Ashkenazi Jewish (ASJ)
AF:
AC:
0
AN:
5120
East Asian (EAS)
AF:
AC:
14
AN:
11394
South Asian (SAS)
AF:
AC:
0
AN:
708
European-Finnish (FIN)
AF:
AC:
0
AN:
434
Middle Eastern (MID)
AF:
AC:
0
AN:
490
European-Non Finnish (NFE)
AF:
AC:
0
AN:
50058
Other (OTH)
AF:
AC:
0
AN:
6754
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.511
Heterozygous variant carriers
0
1
2
3
4
5
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome Data not reliable, filtered out with message: AS_VQSR AF: 0.00000658 AC: 1AN: 152052Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74260 show subpopulations
GnomAD4 genome
Data not reliable, filtered out with message: AS_VQSR
AF:
AC:
1
AN:
152052
Hom.:
Cov.:
32
AF XY:
AC XY:
1
AN XY:
74260
show subpopulations
African (AFR)
AF:
AC:
0
AN:
41386
American (AMR)
AF:
AC:
0
AN:
15260
Ashkenazi Jewish (ASJ)
AF:
AC:
0
AN:
3472
East Asian (EAS)
AF:
AC:
1
AN:
5196
South Asian (SAS)
AF:
AC:
0
AN:
4812
European-Finnish (FIN)
AF:
AC:
0
AN:
10586
Middle Eastern (MID)
AF:
AC:
0
AN:
316
European-Non Finnish (NFE)
AF:
AC:
0
AN:
68020
Other (OTH)
AF:
AC:
0
AN:
2092
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.425
Heterozygous variant carriers
0
0
1
1
2
2
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
ClinVar
ClinVar submissions as Germline
View on ClinVar Significance:Uncertain significance
Revision:criteria provided, single submitter
Pathogenic
VUS
Benign
Condition
-
1
-
Benign hereditary chorea (1)
-
1
-
Brain-lung-thyroid syndrome (1)
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.